Chaoqin Guo

ORCID: 0009-0001-9972-322X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Ubiquitin and proteasome pathways
  • RNA Research and Splicing
  • RNA modifications and cancer
  • Cancer, Hypoxia, and Metabolism
  • Endoplasmic Reticulum Stress and Disease
  • Cancer-related Molecular Pathways
  • Fibroblast Growth Factor Research
  • Protein Tyrosine Phosphatases
  • Mosquito-borne diseases and control
  • Glycosylation and Glycoproteins Research
  • Immune cells in cancer
  • Cancer-related molecular mechanisms research
  • Viral Infections and Outbreaks Research
  • ATP Synthase and ATPases Research
  • Viral Infections and Vectors

Hangzhou Medical College
2023-2024

Hepatocellular carcinoma(HCC) is one of the most common tumors in world. Human insulin-like growth factor 2(IGF2) mRNA binding protein 2(IGF2BP2) plays an important role progression hepatocellular carcinoma. Additionally, long non-coding RNA(lncRNA) has been confirmed as a key regulator carcinoma occurrence. However, function TRPC7-AS1 not verified The research results revealed that high IGF2BP2 expression was associated with decreased survival rate patients Furthermore, knockdown inhibited...

10.1016/j.cellsig.2024.111078 article EN cc-by-nc Cellular Signalling 2024-02-04

Immune-checkpoint blockade (ICB) therapies have been widely used in clinical treatment of cancer patients, but only 20–30% patients benefit from immunotherapy. Therefore, it is important to decipher the molecular mechanism resistance ICB and develop new combined strategies. PD-L1 up-regulation tumor cells contributes occurrence immune escape. Increasing evidence shows that its transcription level affected by multiple factors, which limits objective response rate ICB. Fibroblast growth factor...

10.1016/j.biopha.2023.115955 article EN Biomedicine & Pharmacotherapy 2023-12-03

During an outbreak of hemorrhagic fever with renal syndrome in the Anhui Province China, a door-to-door survey was conducted all 10,024 residents eight village communities. The incidence rates were higher males than females and adults children. Of surveyed, however, those who had slept on ground or been engaged heavy farm work at significantly risk illness wooden beds did light work. Among men gave history sleeping straw huts drained swamp, attack rate 2.33 times it for exclusively their...

10.1093/infdis/152.1.137 article EN The Journal of Infectious Diseases 1985-07-01

Colorectal cancer (CRC) is one of the cancers with high incidence and mortality rates worldwide. In China, there are approximately 400,000 new CRC cases each year, seriously endangering people's life health. Transforming growth factor β-stimulated clone 22 domain family, member 2 (TSC22D2) widely expression in cancers, but role TSC22D2 still unknown.

10.2147/ott.s449244 article EN OncoTargets and Therapy 2024-03-01

Hepatocellular carcinoma (HCC) is one of the most prevalent cancers worldwide with a poor clinical prognosis. Protein phosphatase 1 regulatory subunit 14B (PPP1R14B) an unidentified protein that associated occurrence and development various cancers. Recently, PPP1R14B was found to contribute paclitaxel resistance cell progression in triple-negative breast cancer; however, role HCC unknown. Here, we highly expressed tissues, which suggested Knockdown significantly inhibited survival...

10.1016/j.bbamcr.2024.119840 article EN cc-by-nc Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 2024-08-30

Ubiquitin-specific peptidase 24 (USP24), a member of the deubiquitinase family, plays an important role in tumor regulation. However, USP24 Hepatocellular carcinoma(HCC)is unknown. The aim our study was to explore HCC seek new therapeutic targets for HCC. In this study, we found that aberrantly upregulated tissues and predicted poor prognosis. markedly promoted proliferation progression vitro vivo. Mechanistically, binds necrosis factor receptor-associated 2(TRAF2) inhibits its degradation,...

10.1016/j.bcp.2024.116473 article EN cc-by-nc-nd Biochemical Pharmacology 2024-08-09
Coming Soon ...